Evidence that interfering with tau aggregation through immunotherapy may be possible is provided by murine antibody DC8E8 which also targets monomeric tau, inhibits tau aggregation in vitro, and reduces tau pathology in a murine AD model [27]. Here, MAPT is linked to Alzheimer disease.